Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Royalty Pharma (NASDAQ:RPRX) and raised the price target from $53 to $54.
October 11, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Royalty Pharma and raised the price target from $53 to $54, which could potentially lead to an increase in the stock's price.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for Royalty Pharma. The increase in the price target from $53 to $54 suggests that the analyst believes the stock has potential for further growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100